newsfilter
← Latest News
GlobeNewswire·

Morphic Announces Corporate Highlights and Financial Results for the Second Quarter 2023

-Reported positive topline results from EMERALD-1 study of MORF-057 in ulcerative colitis- -Continued enrollment on target in EMERALD-2 Phase 2b trial of MORF-057 in ulcerative colitis- -Greater than $730 million